The weekly litigation news digest is live. Subscribe now

IP Verse

Exelixis competitive analysis

Latest patents of Exelixis opposed by its competitors

Explore Exelixis's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Dec 25, 2025
Patent NumberPublication DateTitleTotal Oppositions

Get instant alerts of patent oppositions faced by Exelixis

EP2621481
Oct 19, 2022Dual Inhibitors Of Met And Vegf For The Treatment Of Castration- Resistant Prostate Cancer And Osteoblastic Bone Metastases1
EP3630726
Dec 22, 2021Crystalline Solid Forms Of Salts Of N-{4-[(6,7-Dimethoxyquinolin-4-Yl) Oxy]Phenyl}-N'-(4-Fluorphenyl) Cyclopropane-1,1-Dicarboxamide, Processes For Making, And Methods Of Use1
EP2673262
Nov 3, 2021Processes For Preparing Quinoline Compounds And Pharmaceutical Compositions Containing Such Compounds1
EP2593090
Oct 13, 2021C-Met Modulator Pharmaceutical Compositions3
EP3134084
Mar 17, 2021Method Of Treating Lung Adenocarcinoma1

Latest PTAB cases involving Exelixis

Discover the latest PTAB cases involving Exelixis, highlighting their recent legal challenges and patent disputes.

Last updated on: Dec 24, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Exelixis

IPR2025-00427Jan 9, 2025AZURITY PHARMACEUTICALSEXELIXISDiscretionary Denial
IPR2025-00210Nov 18, 2024AZURITY PHARMACEUTICALSEXELIXISInstitution Denied

Peer Comparison New

IP litigation analysis comparing Exelixis with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Dec 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
EXELIXIS - 7 - 2
AZURITY PHARMACEUTICALS - - 9 -
GENERICS UK214 - - -
STADA ARZNEIMITTEL11028 - -